Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 123. More products

ATORVASTATIN CALCIUM

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C10A, C10AA) — coverage varies; not interchangeable

  • Fluvastatin (Lescol): general benefit, Not a benefit
  • Lovastatin (Mevacor): general benefit, Not a benefit
  • Pravastatin (Pravachol): general benefit, Not a benefit
  • Rosuvastatin (Crestor): general benefit
  • Simvastatin (Zocor): general benefit, Not a benefit
  • Bezafibrate (Bezalip): general benefit

9 more in the class list below

Ach-Atorvastatin Calcium · DIN 02457741 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Atorvastatin Calcium · DIN 02457741 Manufacturer: Accord Healthcare Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-10-18 · brand ACH-ATORVASTATIN CALCIUM · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Atorvastatin Calcium: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94478 · Verify on the e-Formulary ↗ (DIN 02457741)

Source record
DIN 02457741: Ach-Atorvastatin Calcium Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id ACH Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457741 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94478
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: resolved shortage (ended 2026-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457741
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Atorvastatin · DIN 02295261 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Atorvastatin · DIN 02295261 Manufacturer: Apotex Inc.; listing date 2010-06-18 Health Canada: Marketed since 2010-05-19 · brand APO-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78058 · Verify on the e-Formulary ↗ (DIN 02295261)

Source record
DIN 02295261: Apo-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295261 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78058
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: resolved shortage (ended 2025-01-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295261
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atorvastatin · DIN 02348705 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Atorvastatin · DIN 02348705 Manufacturer: Sanis Health Inc.; listing date 2011-12-15 Health Canada: Marketed since 2025-05-29 · brand ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83405 · Verify on the e-Formulary ↗ (DIN 02348705)

Source record
DIN 02348705: Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02348705 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83405
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: resolved shortage (ended 2025-06-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02348705
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atorvastatin · DIN 02545462 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Atorvastatin · DIN 02545462 Manufacturer: Teva Canada Limited; listing date 2026-03-31 Health Canada: Marketed since 2026-01-13 · brand ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103422 · Verify on the e-Formulary ↗ (DIN 02545462)

Source record
DIN 02545462: Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545462 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103422
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545462
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atorvastatin-10 · DIN 02411350 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Atorvastatin-10 · DIN 02411350 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2013-10-23 · brand ATORVASTATIN-10 · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Atorvastatin-10: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89596 · Verify on the e-Formulary ↗ (DIN 02411350)

Source record
DIN 02411350: Atorvastatin-10 Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411350 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89596
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: discontinued (2019-05-30, reported by SIVEM PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411350
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Atorvastatin · DIN 02407256 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Atorvastatin · DIN 02407256 Manufacturer: Auro Pharma Inc.; listing date 2013-09-27 Health Canada: Marketed since 2018-04-14 · brand AURO-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89196 · Verify on the e-Formulary ↗ (DIN 02407256)

Source record
DIN 02407256: Auro-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id AUR Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407256 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89196
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: resolved shortage (ended 2022-09-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407256
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Atorvastatin · DIN 02481189 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Atorvastatin · DIN 02481189 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2024-04-23 · brand BIO-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Biomed pharma · schedule Prescription
Check this DIN again · Health Canada product record

Bio-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97130 · Verify on the e-Formulary ↗ (DIN 02481189)

Source record
DIN 02481189: Bio-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id BMP Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481189 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97130
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481189
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Atorvastatin Calcium · DIN 02504197 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Atorvastatin Calcium · DIN 02504197 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Health Canada: Marketed since 2025-10-17 · brand JAMP ATORVASTATIN TABLETS · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Atorvastatin Calcium: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99363 · Verify on the e-Formulary ↗ (DIN 02504197)

Source record
DIN 02504197: Jamp Atorvastatin Calcium Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02504197 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99363
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02504197
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lipitor · DIN 02230711 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Lipitor (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lipitor · DIN 02230711 Manufacturer: Upjohn Canada ULC; listing date 1997-08-28 Health Canada: Marketed since 2023-08-02 · brand LIPITOR · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49973 · Verify on the e-Formulary ↗ (DIN 02230711)

Source record
DIN 02230711: Lipitor Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id UJC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.1864; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230711 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49973
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230711
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Atorvastatin · DIN 02471167 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Atorvastatin · DIN 02471167 Manufacturer: Mantra Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2024-10-10 · brand M-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96027 · Verify on the e-Formulary ↗ (DIN 02471167)

Source record
DIN 02471167: M-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id MAT Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471167 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96027
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471167
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Atorvastatin · DIN 02454017 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Atorvastatin · DIN 02454017 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2016-10-27 Health Canada: Marketed since 2017-05-12 · brand MAR-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94054 · Verify on the e-Formulary ↗ (DIN 02454017)

Source record
DIN 02454017: Mar-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02454017 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94054
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02454017
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Atorvastatin · DIN 02479508 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Atorvastatin · DIN 02479508 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-04-30 Health Canada: Marketed since 2022-11-08 · brand MINT-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97017 · Verify on the e-Formulary ↗ (DIN 02479508)

Source record
DIN 02479508: Mint-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479508 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97017
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: resolved shortage (ended 2024-01-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479508
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Atorvastatin · DIN 02392933 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Atorvastatin · DIN 02392933 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2014-07-30 Health Canada: Marketed since 2014-06-03 · brand MYLAN-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87820 · Verify on the e-Formulary ↗ (DIN 02392933)

Source record
DIN 02392933: Mylan-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id MYL Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02392933 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87820
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02392933
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Atorvastatin · DIN 02476517 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Atorvastatin · DIN 02476517 Manufacturer: Nora Pharma; listing date 2020-09-30 Health Canada: Marketed since 2024-03-22 · brand NRA-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96687 · Verify on the e-Formulary ↗ (DIN 02476517)

Source record
DIN 02476517: NRA-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id NRA Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476517 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96687
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02476517
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMSC-Atorvastatin · DIN 02507234 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMSC-Atorvastatin · DIN 02507234 Manufacturer: Pharmascience Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-03-18 · brand PMSC-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMSC-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99662 · Verify on the e-Formulary ↗ (DIN 02507234)

Source record
DIN 02507234: PMSC-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507234 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99662
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: active shortage (reported 2025-08-03, estimated to end 2027-06-01, last updated 2026-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507234
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PRZ-Atorvastatin · DIN 02521555 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PRZ-Atorvastatin · DIN 02521555 Manufacturer: Pharmaris Canada Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-19 · brand PRZ-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Pharmaris canada inc · schedule Prescription
Check this DIN again · Health Canada product record

PRZ-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101074 · Verify on the e-Formulary ↗ (DIN 02521555)

Source record
DIN 02521555: PRZ-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id PRZ Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521555 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101074
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02521555
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Atorvastatin · DIN 02324946 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Atorvastatin · DIN 02324946 Manufacturer: Sandoz Canada Inc.; listing date 2010-07-20 Health Canada: Marketed since 2010-05-19 · brand SANDOZ ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81036 · Verify on the e-Formulary ↗ (DIN 02324946)

Source record
DIN 02324946: Sandoz Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id SDZ Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02324946 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81036
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: resolved shortage (ended 2025-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02324946
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Atorvastatin · DIN 02313707 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Atorvastatin · DIN 02313707 Manufacturer: Sun Pharma; listing date 2010-06-18 Health Canada: Marketed since 2026-07-13 · brand SPC-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79921 · Verify on the e-Formulary ↗ (DIN 02313707)

Source record
DIN 02313707: Taro-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id SPC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313707 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79921
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743
Shortage status: resolved shortage (ended 2024-11-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02313707
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Atorvastatin · DIN 02310899 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Atorvastatin · DIN 02310899 Manufacturer: Teva Canada Limited; listing date 2010-06-18 Health Canada: Marketed since 2017-06-06 · brand TEVA-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Atorvastatin: Formulary list price $0.1743/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1743 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79651 · Verify on the e-Formulary ↗ (DIN 02310899)

Source record
DIN 02310899: Teva-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02310899 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79651
Interchangeable products
AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mint-Atorvastatin · DIN 02479508 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743
Shortage status: resolved shortage (ended 2026-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02310899
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Atorvastatin Calcium · DIN 02457768 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Atorvastatin Calcium · DIN 02457768 Manufacturer: Accord Healthcare Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-10-18 · brand ACH-ATORVASTATIN CALCIUM · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 20 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Atorvastatin Calcium: Formulary list price $0.2179/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2179 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94479 · Verify on the e-Formulary ↗ (DIN 02457768)

Source record
DIN 02457768: Ach-Atorvastatin Calcium Raw flags: chronicUseMed=Y, sec3=Y Item: 240600034; group id 296; item number 0647; lccId None; manufacturer id ACH Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2179; ministry $0.2179 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457768 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94479
Interchangeable products
AG-Atorvastatin · DIN 02478153 · $0.2179 Apo-Atorvastatin · DIN 02295288 · $0.2179 Atorvastatin · DIN 02348713 · $0.2179 Atorvastatin · DIN 02475030 · $0.2179 Atorvastatin · DIN 02545470 · $0.2179 Atorvastatin-20 · DIN 02411369 · $0.2179 Auro-Atorvastatin · DIN 02407264 · $0.2179 Bio-Atorvastatin · DIN 02481197 · $0.2179 Jamp Atorvastatin Calcium · DIN 02504200 · $0.2179 Jamp-Atorvastatin · DIN 02391066 · $0.2179 Lipitor · DIN 02230713 · $0.2179 M-Atorvastatin · DIN 02471175 · $0.2179 Mar-Atorvastatin · DIN 02454025 · $0.2179 Mint-Atorvastatin · DIN 02479516 · $0.2179 Mylan-Atorvastatin · DIN 02392941 · $0.2179 NRA-Atorvastatin · DIN 02476525 · $0.2179 PMS-Atorvastatin · DIN 02477157 · $0.2179 PMSC-Atorvastatin · DIN 02507242 · $0.2179 PRZ-Atorvastatin · DIN 02521563 · $0.2179 Ratio-Atorvastatin · DIN 02350319 · $0.2179 Reddy-Atorvastatin · DIN 02417944 · $0.2179 Sandoz Atorvastatin · DIN 02324954 · $0.2179 Taro-Atorvastatin · DIN 02313715 · $0.2179 Teva-Atorvastatin · DIN 02310902 · $0.2179
Shortage status: resolved shortage (ended 2026-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457768
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Atorvastatin · DIN 02295288 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Atorvastatin · DIN 02295288 Manufacturer: Apotex Inc.; listing date 2010-06-18 Health Canada: Marketed since 2010-05-19 · brand APO-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Atorvastatin: Formulary list price $0.2179/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2179 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78059 · Verify on the e-Formulary ↗ (DIN 02295288)

Source record
DIN 02295288: Apo-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600034; group id 296; item number 0647; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2179; ministry $0.2179 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295288 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78059
Interchangeable products
AG-Atorvastatin · DIN 02478153 · $0.2179 Ach-Atorvastatin Calcium · DIN 02457768 · $0.2179 Atorvastatin · DIN 02348713 · $0.2179 Atorvastatin · DIN 02475030 · $0.2179 Atorvastatin · DIN 02545470 · $0.2179 Atorvastatin-20 · DIN 02411369 · $0.2179 Auro-Atorvastatin · DIN 02407264 · $0.2179 Bio-Atorvastatin · DIN 02481197 · $0.2179 Jamp Atorvastatin Calcium · DIN 02504200 · $0.2179 Jamp-Atorvastatin · DIN 02391066 · $0.2179 Lipitor · DIN 02230713 · $0.2179 M-Atorvastatin · DIN 02471175 · $0.2179 Mar-Atorvastatin · DIN 02454025 · $0.2179 Mint-Atorvastatin · DIN 02479516 · $0.2179 Mylan-Atorvastatin · DIN 02392941 · $0.2179 NRA-Atorvastatin · DIN 02476525 · $0.2179 PMS-Atorvastatin · DIN 02477157 · $0.2179 PMSC-Atorvastatin · DIN 02507242 · $0.2179 PRZ-Atorvastatin · DIN 02521563 · $0.2179 Ratio-Atorvastatin · DIN 02350319 · $0.2179 Reddy-Atorvastatin · DIN 02417944 · $0.2179 Sandoz Atorvastatin · DIN 02324954 · $0.2179 Taro-Atorvastatin · DIN 02313715 · $0.2179 Teva-Atorvastatin · DIN 02310902 · $0.2179
Shortage status: resolved shortage (ended 2026-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295288
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atorvastatin · DIN 02348713 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Atorvastatin · DIN 02348713 Manufacturer: Sanis Health Inc.; listing date 2011-12-15 Health Canada: Marketed since 2025-04-29 · brand ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 20 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Atorvastatin: Formulary list price $0.2179/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2179 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83406 · Verify on the e-Formulary ↗ (DIN 02348713)

Source record
DIN 02348713: Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600034; group id 296; item number 0647; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2179; ministry $0.2179 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02348713 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83406
Interchangeable products
AG-Atorvastatin · DIN 02478153 · $0.2179 Ach-Atorvastatin Calcium · DIN 02457768 · $0.2179 Apo-Atorvastatin · DIN 02295288 · $0.2179 Atorvastatin · DIN 02475030 · $0.2179 Atorvastatin · DIN 02545470 · $0.2179 Atorvastatin-20 · DIN 02411369 · $0.2179 Auro-Atorvastatin · DIN 02407264 · $0.2179 Bio-Atorvastatin · DIN 02481197 · $0.2179 Jamp Atorvastatin Calcium · DIN 02504200 · $0.2179 Jamp-Atorvastatin · DIN 02391066 · $0.2179 Lipitor · DIN 02230713 · $0.2179 M-Atorvastatin · DIN 02471175 · $0.2179 Mar-Atorvastatin · DIN 02454025 · $0.2179 Mint-Atorvastatin · DIN 02479516 · $0.2179 Mylan-Atorvastatin · DIN 02392941 · $0.2179 NRA-Atorvastatin · DIN 02476525 · $0.2179 PMS-Atorvastatin · DIN 02477157 · $0.2179 PMSC-Atorvastatin · DIN 02507242 · $0.2179 PRZ-Atorvastatin · DIN 02521563 · $0.2179 Ratio-Atorvastatin · DIN 02350319 · $0.2179 Reddy-Atorvastatin · DIN 02417944 · $0.2179 Sandoz Atorvastatin · DIN 02324954 · $0.2179 Taro-Atorvastatin · DIN 02313715 · $0.2179 Teva-Atorvastatin · DIN 02310902 · $0.2179
Shortage status: resolved shortage (ended 2025-04-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02348713
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atorvastatin · DIN 02545470 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Atorvastatin · DIN 02545470 Manufacturer: Teva Canada Limited; listing date 2026-03-31 Health Canada: Marketed since 2026-01-13 · brand ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 20 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Atorvastatin: Formulary list price $0.2179/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2179 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103423 · Verify on the e-Formulary ↗ (DIN 02545470)

Source record
DIN 02545470: Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600034; group id 296; item number 0647; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2179; ministry $0.2179 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545470 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103423
Interchangeable products
AG-Atorvastatin · DIN 02478153 · $0.2179 Ach-Atorvastatin Calcium · DIN 02457768 · $0.2179 Apo-Atorvastatin · DIN 02295288 · $0.2179 Atorvastatin · DIN 02348713 · $0.2179 Atorvastatin · DIN 02475030 · $0.2179 Atorvastatin-20 · DIN 02411369 · $0.2179 Auro-Atorvastatin · DIN 02407264 · $0.2179 Bio-Atorvastatin · DIN 02481197 · $0.2179 Jamp Atorvastatin Calcium · DIN 02504200 · $0.2179 Jamp-Atorvastatin · DIN 02391066 · $0.2179 Lipitor · DIN 02230713 · $0.2179 M-Atorvastatin · DIN 02471175 · $0.2179 Mar-Atorvastatin · DIN 02454025 · $0.2179 Mint-Atorvastatin · DIN 02479516 · $0.2179 Mylan-Atorvastatin · DIN 02392941 · $0.2179 NRA-Atorvastatin · DIN 02476525 · $0.2179 PMS-Atorvastatin · DIN 02477157 · $0.2179 PMSC-Atorvastatin · DIN 02507242 · $0.2179 PRZ-Atorvastatin · DIN 02521563 · $0.2179 Ratio-Atorvastatin · DIN 02350319 · $0.2179 Reddy-Atorvastatin · DIN 02417944 · $0.2179 Sandoz Atorvastatin · DIN 02324954 · $0.2179 Taro-Atorvastatin · DIN 02313715 · $0.2179 Teva-Atorvastatin · DIN 02310902 · $0.2179
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545470
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atorvastatin-20 · DIN 02411369 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Atorvastatin-20 · DIN 02411369 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2013-10-23 · brand ATORVASTATIN-20 · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Atorvastatin-20: Formulary list price $0.2179/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2179 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89597 · Verify on the e-Formulary ↗ (DIN 02411369)

Source record
DIN 02411369: Atorvastatin-20 Raw flags: chronicUseMed=Y, sec3=Y Item: 240600034; group id 296; item number 0647; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2179; ministry $0.2179 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411369 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89597
Interchangeable products
AG-Atorvastatin · DIN 02478153 · $0.2179 Ach-Atorvastatin Calcium · DIN 02457768 · $0.2179 Apo-Atorvastatin · DIN 02295288 · $0.2179 Atorvastatin · DIN 02348713 · $0.2179 Atorvastatin · DIN 02475030 · $0.2179 Atorvastatin · DIN 02545470 · $0.2179 Auro-Atorvastatin · DIN 02407264 · $0.2179 Bio-Atorvastatin · DIN 02481197 · $0.2179 Jamp Atorvastatin Calcium · DIN 02504200 · $0.2179 Jamp-Atorvastatin · DIN 02391066 · $0.2179 Lipitor · DIN 02230713 · $0.2179 M-Atorvastatin · DIN 02471175 · $0.2179 Mar-Atorvastatin · DIN 02454025 · $0.2179 Mint-Atorvastatin · DIN 02479516 · $0.2179 Mylan-Atorvastatin · DIN 02392941 · $0.2179 NRA-Atorvastatin · DIN 02476525 · $0.2179 PMS-Atorvastatin · DIN 02477157 · $0.2179 PMSC-Atorvastatin · DIN 02507242 · $0.2179 PRZ-Atorvastatin · DIN 02521563 · $0.2179 Ratio-Atorvastatin · DIN 02350319 · $0.2179 Reddy-Atorvastatin · DIN 02417944 · $0.2179 Sandoz Atorvastatin · DIN 02324954 · $0.2179 Taro-Atorvastatin · DIN 02313715 · $0.2179 Teva-Atorvastatin · DIN 02310902 · $0.2179
Shortage status: discontinued (2019-06-07, reported by SIVEM PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411369
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 3 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LIPITOR (atorvastatin calcium) is indicated in adults as an adjunct to lifestyle changes, including diet for: • the reduction of elevated total cholesterol (total-C), LDL-C, triglycerides (TG), apolipoprotein B (apo B), the Total-C/HDL-C ratio and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions, including: • Primary hypercholesterolemia (Type IIa); • Combined (mixed) hyperlipidemia (Type IIb), including familial combined hyperlipidemia, regardless of whether cholesterol or triglycerides are the lipid abnormality of concern; • Dysbetalipoproteinemia (Type III); • Hypertriglyceridemia (Type IV); • Familial hypercholesterolemia (homozygous and heterozygous). For homozygous familial hypercholesterolemia, LIPITOR should be used as an adjunct to treatments such as LDL apheresis, or as monotherapy if such treatments are not available. • the prevention of Cardiovascular Disease, to reduce the risk of … https://pdf.hres.ca/dpd_pm/00081136.PDF PM date: JUL 22, 2025 Source product: LIPITOR; DIN 02230711; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS CADUET (amlodipine besylate/atorvastatin calcium) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate, specifically, patients at cardiovascular risk. CADUET is not for initial therapy. The dose of CADUET should be determined by the titration of individual components (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics Based on the data submitted and reviewed by Health Canada, the safety and efficacy of CADUET in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. However, there have been studies using amlodipine or atorvastatin only in pediatrics (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00081162.PDF PM date: JUL 23, 2025 Source product: CADUET; DIN 02273233; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Atorvastatin-10 · DIN 02411350 Shortage status: discontinued (2019-05-30, reported by SIVEM PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411350

Check this DIN again

PMSC-Atorvastatin · DIN 02507234 Shortage status: active shortage (reported 2025-08-03, estimated to end 2027-06-01, last updated 2026-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507234

Check this DIN again

Atorvastatin-20 · DIN 02411369 Shortage status: discontinued (2019-06-07, reported by SIVEM PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411369

Check this DIN again